Evidence map›Paper›PMID 39741404›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Controlling intracellular protein delivery, tumor colonization and tissue distribution using flhDC in clinically relevant ΔsseJ Salmonella.

Vishnu Raman, Christopher L Hall, Victoria E Wetherby, Samantha A Whitney, Nele Van Dessel, Neil S Forbes

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vishnu RamanDepartment of Chemical Engineering, University of Massachusetts, Amherst, Amherst, MA 01003, USA; Ernest Pharmaceuticals, Inc., Hadley, MA 01035, USA.
Christopher L HallDepartment of Chemical Engineering, University of Massachusetts, Amherst, Amherst, MA 01003, USA; Ernest Pharmaceuticals, Inc., Hadley, MA 01035, USA.
Victoria E WetherbyErnest Pharmaceuticals, Inc., Hadley, MA 01035, USA.
Samantha A WhitneyDepartment of Chemical Engineering, University of Massachusetts, Amherst, Amherst, MA 01003, USA.
Nele Van DesselErnest Pharmaceuticals, Inc., Hadley, MA 01035, USA.
Neil S ForbesDepartment of Chemical Engineering, University of Massachusetts, Amherst, Amherst, MA 01003, USA; Molecular and Cell Biology Program, University of Massachusetts, Amherst, Amherst, MA 01003, USA; Institute for Applied Life Science, University of Massachusetts, Amherst, Amherst, MA 01003, USA; Department of Microbiology, University of Massachusetts, Amherst, Amherst, MA 01003, USA. Electronic address: forbes@umass.edu.

Funding

Targeting epigenetic regulators using bacterial macromolecule deliveryR01CA188382 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI FORBES, NEIL S. · 2014 to 2018
$1.6M
An engineered bacterial reporter gene fusion for radiotheranosticsR21CA287211 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHEAL, SARAH MARIE, FORBES, NEIL S. · 2024 to 2024
$435k
Salmonella as a vector for delivery of oncolytic viruses to hepatocellular carcinomaR21CA293765 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI FORBES, NEIL S. · 2024 to 2024
$402k
Bacterial delivery of pro-apoptotic proteins in advanced hepatocellular carcinoma.R43CA250941 · NCI · ERNEST PHARMACEUTICALS, LLC · PI VAN DESSEL, NELE · 2020 to 2020
$284k
NCI NIH HHS R01 CA188382NCI NIH HHS R21 CA287211NCI NIH HHS R21 CA293765NCI NIH HHS R43 CA250941
6 · The paper itself

Abstract

Effectively targeting intracellular pathways in cancers requires a system that specifically delivers to tumors and internalizes into cancer cells. To achieve this goal, we developed intracellular-delivering (ID) Salmonella with controllable expression of flhDC to regulate flagella production and cell invasion. We hypothesized that controlling flhDC would overcome the poor colonization seen in prior clinical trials. To test this hypothesis, we incorporated the aspirin-responsive Psal promoter and tuned flhDC expression with ssra degradation tags. In tumor-bearing mice, controlling flhDC increased protein release, tissue dispersion, and tumor colonization more than 10 million times. We discovered that inducing flhDC increases escape from intracellular vacuoles; however, deleting sseJ prevented escape and further increased protein delivery. Delivering constitutively active caspase-3 with ID-f-s Salmonella (ΔsseJ and induced Psal-flhDC) induced cell death in pancreatic, breast, and liver cancer cells and reduced the growth of breast tumors. This clinically ready strain preferentially colonized metastatic breast tissue 280 and 800 times more than surrounding healthy tissue in the lung and liver, respectively. By precisely controlling tumor colonization and cell invasion, this strain overcomes critical limitations of bacterial therapy and will enable treatment of many hard-to-treat cancers.

Indexed as

Bacterial ProteinsNeoplasmsSalmonellaAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMiceTissue DistributionXenograft Model Antitumor AssaysBacterial Proteinsaspirinbacterial cancer therapyflagellaintracellular deliverylive bacterial therapeuticmetastatic cancer therapymicrobial therapySalmonellasynthetic biologytargeted cancer therapy

Identifiers

PMID39741404
PMCPMC11852948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.